---
title: Adoptive Cell Therapy Long-term Follow-up (LTFU) Study
nct_id: NCT03391778
overall_status: RECRUITING
phase: PHASE1
sponsor: USWM CT, LLC
study_type: INTERVENTIONAL
primary_condition: Neoplasms
countries: United States, Australia, Canada, Germany, Italy, Netherlands, Spain, United Kingdom
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT03391778.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT03391778"
ct_last_update_post_date: 2026-03-03
last_seen_at: "2026-05-12T06:46:02.985Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Adoptive Cell Therapy Long-term Follow-up (LTFU) Study

**Official Title:** Long-Term Follow-Up (LTFU) of Participants Treated With ADP Adoptive Cell Therapies

**NCT ID:** [NCT03391778](https://clinicaltrials.gov/study/NCT03391778)

## Key Facts

- **Status:** RECRUITING
- **Phase:** PHASE1
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 250
- **Lead Sponsor:** USWM CT, LLC
- **Conditions:** Neoplasms
- **Start Date:** 2018-04-09
- **Completion Date:** 2032-04-01
- **CT.gov Last Update:** 2026-03-03

## Brief Summary

This trial will evaluate long term safety of participants who have received AdaptImmune (ADP) adoptive cell therapy for up to 15 years following last adoptive cell therapy infusion.

## Detailed Description

Participants who received a ADP adoptive cell therapy will be enrolled in this non-therapeutic, multi-center, long term follow-up (LTFU) study and will be followed for up to 15 years post-infusion of lentiviral vector-based adoptive cell therapy. Participants will be monitored for safety following last adoptive cell therapy infusion.

## Eligibility

- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* Participants who have received at least one dose of ADP adoptive cell therapy agent.
* Participants who have completed ADP sponsored or supported interventional study or have withdrawn from it.
* Participants who have completed treatment as part of managed access to a GSK adoptive cell therapy.
* Contraceptive use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
* The investigator is responsible for review of medical history.
* Capable of giving signed informed consent.

Exclusion Criteria:

\- None
```

## Arms

- **Participants receiving ADP adoptive cell therapy** (EXPERIMENTAL)

## Interventions

- **ADP adoptive cell therapy** (BIOLOGICAL) — No study drug is administered in this study. Participants who received ADP adoptive cell therapy in a previous trial will be evaluated in this trial for long-term safety and efficacy.

## Primary Outcomes

- **Number of participants with delayed adverse events (AEs) and serious adverse events (SAEs)** _(time frame: 15 years post last treatment)_ — AEs will be collected.

## Secondary Outcomes

- **Number of participants with Vesicular Stomatitis Virus G protein (VSV-G) Deoxyribonucleic acid (DNA) copies in peripheral blood samples** _(time frame: 15 years)_
- **Number of participants with Woodchuck hepatitis virus post-transcriptional regulatory element (WPRE) or Psi DNA copies in peripheral blood samples.** _(time frame: 15 years)_
- **Number of participants with integrated vector sequences and vector integration patterns identified in peripheral blood samples** _(time frame: 15 years)_
- **Number of deaths** _(time frame: 15 years)_
- **Time to death** _(time frame: 15 years)_

## Locations (24)

- Emory University School of Medicine, Atlanta, Georgia, United States — _RECRUITING_
- ADP Investigational Site, Baltimore, Maryland, United States — _RECRUITING_
- National Cancer Institute - Center for Cancer Research, Bethesda, Maryland, United States — _COMPLETED_
- University of Michigan, Ann Arbor, Michigan, United States — _RECRUITING_
- Washington University School of Medicine in St. Louis, St Louis, Missouri, United States — _RECRUITING_
- Memorial Sloan Kettering Cancer Center - New York, New York, New York, United States — _RECRUITING_
- Duke University Medical Center, Durham, North Carolina, United States — _RECRUITING_
- Oregon Health and Science University, Portland, Oregon, United States — _RECRUITING_
- University of Pennsylvania, Philadelphia, Pennsylvania, United States — _RECRUITING_
- University of Pittsburgh Medical Center (UPMC) Hillman Cancer Center, Pittsburgh, Pennsylvania, United States — _RECRUITING_
- University of Texas Southwestern Medical Center, Dallas, Texas, United States — _RECRUITING_
- University of Texas MD Anderson Cancer Center, Houston, Texas, United States — _RECRUITING_
- Froedtert Hospital, Milwaukee, Wisconsin, United States — _RECRUITING_
- Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia — _RECRUITING_
- Princess Margaret Cancer Centre, Toronto, Ontario, Canada — _RECRUITING_
- Hôpital Maisonneuve-Rosemont, Montreal, Quebec, Canada — _RECRUITING_
- Klinikum rechts der Isar der Technischen Universität München, Munich, Bavaria, Germany — _RECRUITING_
- Uniklinik Köln, Cologne, North Rhine-Westphalia, Germany — _RECRUITING_
- Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, Lombardy, Italy — _RECRUITING_
- Antoni Van Leeuwenhoek Ziekenhuis, Amsterdam, Netherlands — _RECRUITING_
- Hospital Universitario Virgen del Rocío, Seville, Spain — _RECRUITING_
- University College London Hospitals NHS Foundation Trust, London, United Kingdom — _RECRUITING_
- USWM CT Investigational Site, Manchester, United Kingdom — _RECRUITING_
- The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom — _RECRUITING_

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.emory university school of medicine|atlanta|georgia|united states` — added _(2026-05-12)_
- `locations.adp investigational site|baltimore|maryland|united states` — added _(2026-05-12)_
- `locations.national cancer institute - center for cancer research|bethesda|maryland|united states` — added _(2026-05-12)_
- `locations.university of michigan|ann arbor|michigan|united states` — added _(2026-05-12)_
- `locations.washington university school of medicine in st. louis|st louis|missouri|united states` — added _(2026-05-12)_
- `locations.memorial sloan kettering cancer center - new york|new york|new york|united states` — added _(2026-05-12)_
- `locations.duke university medical center|durham|north carolina|united states` — added _(2026-05-12)_
- `locations.oregon health and science university|portland|oregon|united states` — added _(2026-05-12)_
- `locations.university of pennsylvania|philadelphia|pennsylvania|united states` — added _(2026-05-12)_
- `locations.university of pittsburgh medical center (upmc) hillman cancer center|pittsburgh|pennsylvania|united states` — added _(2026-05-12)_
- `locations.university of texas southwestern medical center|dallas|texas|united states` — added _(2026-05-12)_
- `locations.uswm ct investigational site|manchester||united kingdom` — added _(2026-05-12)_
- `locations.university of texas md anderson cancer center|houston|texas|united states` — added _(2026-05-12)_
- `locations.froedtert hospital|milwaukee|wisconsin|united states` — added _(2026-05-12)_
- `locations.peter maccallum cancer centre|melbourne|victoria|australia` — added _(2026-05-12)_
- `locations.princess margaret cancer centre|toronto|ontario|canada` — added _(2026-05-12)_
- `locations.hôpital maisonneuve-rosemont|montreal|quebec|canada` — added _(2026-05-12)_
- `locations.klinikum rechts der isar der technischen universität münchen|munich|bavaria|germany` — added _(2026-05-12)_
- `locations.uniklinik köln|cologne|north rhine-westphalia|germany` — added _(2026-05-12)_
- `locations.fondazione irccs - istituto nazionale dei tumori|milan|lombardy|italy` — added _(2026-05-12)_
- `locations.antoni van leeuwenhoek ziekenhuis|amsterdam||netherlands` — added _(2026-05-12)_
- `locations.hospital universitario virgen del rocío|seville||spain` — added _(2026-05-12)_
- `locations.university college london hospitals nhs foundation trust|london||united kingdom` — added _(2026-05-12)_
- `locations.the royal marsden nhs foundation trust|sutton||united kingdom` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT03391778.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT03391778*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*